GSK li­cens­es Ion­is' ex­per­i­men­tal hep B treat­ments in up to $262M deal

GSK $GSK may have walked away from two of Io­n­is’ $IONS an­ti­sense drugs (in­clud­ing the now-ap­proved Tegse­di) in 2017 — but the British drug­mak­er held on as a part­ner to the biotech­nol­o­gy com­pa­ny’s ex­per­i­men­tal he­pati­tis B treat­ments.

On Tues­day, GSK ex­er­cised its op­tion to li­cense Io­n­is’ drugs — IO­N­IS-HBVRx and IO­N­IS-HBV-LRx — fol­low­ing pos­i­tive mid-stage da­ta. In re­turn, Io­n­is re­ceives up to $262 mil­lion in mile­stone pay­ments, in­clud­ing a $25 mil­lion li­cense fee. In ad­di­tion, Io­n­is is al­so el­i­gi­ble to re­ceive tiered roy­al­ties on net sales. Now, GSK is re­spon­si­ble for all de­vel­op­ment, reg­u­la­to­ry and com­mer­cial­iza­tion ac­tiv­i­ties and costs for the two drugs.

Hep B is trans­mit­ted through con­tact with blood and bod­i­ly flu­ids of an in­fect­ed per­son and is a high­ly in­fec­tious virus, 50 to 100 times more in­fec­tious than HIV — even slight laps­es in in­fec­tion con­trol can re­sult in pa­tient-to-pa­tient trans­mis­sion. The chron­ic in­fec­tion, which af­fects more than 200 mil­lion glob­al­ly, can lead to life-threat­en­ing health con­di­tions, in­clud­ing cir­rho­sis, liv­er fail­ure and liv­er can­cer. Cur­rent treat­ments that are ef­fec­tive in re­duc­ing cir­cu­lat­ing virus in the blood, do not ef­fi­cient­ly in­hib­it anti­gen pro­duc­tion and se­cre­tion, which are as­so­ci­at­ed with poor prog­no­sis.

The an­ti­sense drugs are en­gi­neered to ad­dress the root cause of the dis­ease — by re­duc­ing the pro­duc­tion of vi­ral pro­teins as­so­ci­at­ed with hep B in­fec­tion and repli­ca­tion, in­clud­ing hep B sur­face anti­gen, which is found in both acute and chron­ic in­fec­tions. Mean­while, GSK al­ready sells a hep B vac­cine called En­ger­ix-B.

Io­n­is has a myr­i­ad of big phar­ma part­ner­ships un­der its belt, in­clud­ing Roche, Bio­gen, Bay­er and As­traZeneca. Un­der chief Stan­ley Crooke, who found­ed the com­pa­ny about thir­ty years ago, Io­n­is has honed a mod­el in which it de­vel­ops an­ti­sense prod­ucts for a pletho­ra of in­di­ca­tions, de-risks them in the clin­ic and then se­cures a phar­ma part­ner to con­duct piv­otal tri­als and com­mer­cial­ize. In re­turn, the com­pa­ny prof­its from a steady stream of up­front and mile­stone pay­ments, as well as roy­al­ties. Last De­cem­ber, Crooke dis­closed plans to tran­si­tion to the role of ex­ec­u­tive chair­man in 2020.

Hal Bar­ron

Un­der re­search chief Hal Bar­ron, GSK has been work­ing on con­jur­ing up some ex­cite­ment for its pipeline by large­ly fo­cus­ing on on­col­o­gy, al­though oth­er ar­eas that are un­der­served are al­so of in­ter­est. In an in­ter­view with the Fi­nan­cial Times in Ju­ly, he said that tak­ing “smart risks” in R&D is how he sees the once glacial gi­ant trans­form­ing its re­search work. “(O)nce you start fear­ing fail­ure, you be­come so con­ser­v­a­tive that you end up ba­si­cal­ly mov­ing to­wards things that are ob­vi­ous­ly go­ing to work and there­fore like­ly to be not very in­no­v­a­tive . . . And, ul­ti­mate­ly, it’s a death spi­ral.”

So­cial im­age: GSK, AP Im­ages


A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.